Science-First Approach to Benefit-Risk Analysis

The BRAT framework was originally developed by the Pharmaceutical Research and Manufacturers of America (PhRMA) and adopted by FDA's Center for Drug Evaluation and Research (CDER) as a structured approach to qualitative-to-quantitative benefit-risk assessment. It provides a systematic process for defining, identifying, sourcing, and evaluating the benefits and risks of medical products within a transparent decision-making framework.

How ArcaScience operationalizes BRAT:

• Define the decision context: AI-assisted stakeholder identification and decision-framing templates pre-populated from the product's regulatory history and therapeutic area context
• Identify outcomes: Automated systematic evidence review using NLP models to extract benefit and risk endpoints from clinical trial publications, CSRs, and regulatory documents
• Source data: Automated population of BRAT value trees and effects tables from the AS Profiling Base 100B® integrated evidence dataset, spanning FAERS, EudraVigilance, clinical trials, and published literature
• Customize the framework: Interactive weighting and visualization tools that allow teams to explore how different stakeholder perspectives affect the benefit-risk balance
• Assess and communicate: Automated generation of effects tables, forest plots, and structured narratives in FDA-compatible and EMA-compatible formats

The platform reduces the manual effort of a complete BRAT assessment from 8–12 weeks to under 2 weeks, while maintaining full traceability from every data point to its source document.

Multi-Criteria Decision Analysis provides a rigorous quantitative method for evaluating trade-offs between multiple benefit and risk criteria. Endorsed by the EMA's PROTECT initiative and increasingly adopted by FDA reviewers, MCDA translates complex multi-dimensional benefit-risk profiles into transparent, weighted scoring models that expose the assumptions underlying every regulatory decision.

ArcaScience MCDA capabilities:

• Weighted scoring models: Configurable criteria weighting with swing weighting, direct rating, and discrete choice methods for eliciting stakeholder preferences from clinicians, regulators, patients, and payers
• Sensitivity analysis: One-way, two-way, and probabilistic sensitivity analyses that show how the benefit-risk conclusion changes under different weighting assumptions — essential for demonstrating robustness to regulators
• Stochastic MCDA: Monte Carlo simulation incorporating uncertainty from data heterogeneity, sample size limitations, and between-study variability to produce probabilistic benefit-risk characterizations
• Scenario modeling: Side-by-side comparison of benefit-risk profiles across subpopulations, dosing regimens, and comparator therapies with interactive visualization

The platform generates interactive visualizations that allow decision-makers to explore how different weighting assumptions affect the overall benefit-risk balance, with full export to regulatory-ready formats.

PrOACT-URL is a structured decision framework developed for complex benefit-risk problems where multiple stakeholders, competing objectives, and deep uncertainty make traditional analytical approaches insufficient. The framework decomposes benefit-risk decisions into eight manageable elements, each addressed systematically:

• Problem — Define the decision context: what product, what indication, what lifecycle stage, what regulatory jurisdiction
• Objectives — Identify what matters: efficacy endpoints, safety concerns, patient-reported outcomes, quality of life measures
• Alternatives — Define the comparators: placebo, active comparator, standard of care, no treatment
• Consequences — Quantify the effects: treatment effects, adverse event rates, time-to-event data
• Trade-offs — Evaluate the balance: how do benefits weigh against risks for different patient populations
• Uncertainty — Characterize what we do not know: confidence intervals, data gaps, model uncertainty
• Risk tolerance — Incorporate stakeholder risk attitudes: regulator, prescriber, and patient risk preferences
• Linked decisions — Consider downstream consequences: label restrictions, REMS requirements, post-marketing commitments

ArcaScience implements PrOACT-URL as a guided workflow within the platform, with each step supported by AI-assisted data retrieval, quantitative analysis, and structured documentation. This framework is particularly valuable for advisory committee preparation and PRAC referral responses.

NNT (Number Needed to Treat) and NNH (Number Needed to Harm) provide intuitive, clinically meaningful metrics for quantifying treatment effects. These measures translate relative risk reductions and increases into absolute patient-level impact, making benefit-risk communication accessible to clinicians, regulators, and patients alike.

Platform implementation:

• Automated NNT/NNH computation: Calculated from clinical trial data, meta-analyses, and real-world evidence with confidence intervals and subgroup stratification
• Likelihood of Being Helped or Harmed (LHH): NNT/NNH ratios computed across all major benefit-risk endpoint pairs to provide a single summary metric of the benefit-risk balance
• Population-adjusted estimates: NNT and NNH values adjusted for baseline risk in specific patient populations using real-world prevalence and incidence data from the AS Profiling Base
• Time-horizon modeling: Duration-specific NNT/NNH calculations that show how the benefit-risk balance evolves over treatment duration — critical for chronic therapies

NNT/NNH analyses are automatically integrated into effects tables and benefit-risk summaries, providing the quantitative backbone for structured regulatory communication in CTD Module 2.5 and PBRER documents.

Effects tables and value trees are the primary visual outputs recommended by both the FDA and EMA for structured benefit-risk communication. ArcaScience auto-generates both formats from the integrated evidence base:

• Effects tables: Summarize key outcomes with effect sizes, confidence intervals, NNT/NNH values, strength of evidence grading, and data source provenance for each endpoint
• Value trees: Hierarchical decomposition of the benefit-risk balance into constituent criteria, with quantitative weights and scores at each node
• Multi-format output: Generated simultaneously in FDA-compatible (Structured Benefit-Risk Framework) and EMA-compatible (PROTECT) layouts from a single evidence base

These structured outputs are directly aligned with the FDA's Structured Benefit-Risk Assessment Framework (PDUFA V commitment), EMA's Benefit-Risk Methodology Project (PROTECT) recommendations, and ICH M4E(R2) guidance on CTD structure.

ArcaScience's frameworks are specifically designed to meet the methodological expectations articulated in current regulatory guidance. Every framework implementation in the platform maps directly to regulatory requirements:

• FDA: Structured Benefit-Risk Assessment Framework (PDUFA V/VI commitment), incorporating the dimensions of Analysis of Condition, Current Treatment Options, Benefit, Risk, and Risk Management. Platform outputs map directly to the five-dimension framework used by FDA review divisions.
• EMA: PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium) recommendations for quantitative benefit-risk methods, including MCDA and structured expert elicitation approaches endorsed by PRAC.
• PMDA: Japan's Pharmaceuticals and Medical Devices Agency benefit-risk assessment expectations, including J-PSUR and RMP requirements with Japanese-language output support.
• Health Canada: Alignment with Health Canada's benefit-risk framework and Summary Basis of Decision requirements.
• ICH: M4E(R2) guidance on the Common Technical Document structure for benefit-risk presentation, E2C(R2) for PBRER, and E2E for pharmacovigilance planning.

ArcaScience maintains rigorous standards for model training, validation, and ongoing governance:

Training Data Sources:

• Publicly available pharmacovigilance databases (FAERS, EudraVigilance quarterly extracts, VigiBase aggregate data)
• Published biomedical literature (PubMed/MEDLINE corpus, Embase, Cochrane Library systematic reviews)
• Clinical trial registries and results databases (ClinicalTrials.gov, EU Clinical Trials Register)
• Regulatory submission archives and label change histories across FDA, EMA, and PMDA

Model Governance:

• Validation against known signals: Every signal detection model is validated against a reference set of historically confirmed and refuted safety signals across 12 therapeutic areas
• Regular retraining: Quarterly model retraining cycles with updated data, followed by full revalidation before production deployment
• Bias monitoring: Continuous monitoring for demographic bias, geographic bias, and temporal drift in model performance, with automated alerts for statistically significant performance degradation
• Complete lineage: Version-controlled model artifacts, training data snapshots, hyperparameter configurations, and validation results for every model in production

Performance Metrics:

• Signal detection sensitivity: 92.4% for confirmed safety signals in retrospective validation (vs. 71.8% for traditional disproportionality alone)
• Signal detection specificity: 87.1%, reducing false-positive burden by 40% compared to unaugmented statistical methods
• Positive predictive value: 68.3% for signal triage classification, validated across oncology, immunology, neurology, and cardiology therapeutic areas
• NLP extraction accuracy: 96.2% MedDRA coding accuracy at Preferred Term level; 94.7% for drug-event relation extraction from unstructured narratives

ArcaScience's AI approach is fundamentally different from applying general-purpose large language models to pharmacovigilance tasks. This distinction is not academic — it is the difference between outputs that regulators can trust and outputs that they cannot:

• Deterministic outputs: For signal detection and quantitative analysis, models produce reproducible numerical results, not probabilistic text generation. The same input data always produces the same output.
• Full traceability: Every model output links back to specific input data points with a complete provenance chain, enabling the audit trails required by 21 CFR Part 11 and GVP Module IX.
• No hallucination risk: Quantitative models do not generate synthetic facts. NLP extraction models are constrained to entities present in source documents with provenance tracking. There is no generative component producing unsourced claims.
• Regulatory validation: Each model undergoes formal validation per GAMP 5 Category 5 software validation principles, with documented IQ/OQ/PQ protocols and ongoing performance qualification.

The AS Profiling Base integrates data across the full spectrum of pharmacovigilance and clinical evidence:

• Spontaneous reporting databases: FDA FAERS (quarterly AERS extracts since 2004), EMA EudraVigilance (EV Web access and line listings), WHO VigiBase (aggregate and case-level data via UMC), plus national databases including MHRA Yellow Card, ANSM, and BfArM
• Clinical trial databases: ClinicalTrials.gov (400,000+ registered studies), EU Clinical Trials Register, individual patient-level data from sponsor datasets integrated via CDISC SDTM/ADaM standards
• Published literature: PubMed/MEDLINE (36M+ citations), Embase, Cochrane Library, with automated systematic review and meta-analysis capabilities
• Real-world evidence: Claims databases, electronic health records, patient registries, and structured social media pharmacovigilance monitoring for early signal detection
• Regulatory intelligence: Label changes, Dear Healthcare Provider letters, risk communications, REMS programs, and risk management plans across FDA, EMA, PMDA, and Health Canada

Raw data from heterogeneous sources is harmonized through a multi-stage pipeline designed for both accuracy and auditability:

• MedDRA coding: Adverse events standardized to MedDRA (Medical Dictionary for Regulatory Activities) at all hierarchy levels — SOC, HLGT, HLT, PT, and LLT — using AI-assisted coding validated against expert manual coding
• WHODrug mapping: Drug substances identified and normalized using WHO Drug Dictionary Enhanced, resolving brand names, generics, active substances, and common misspellings
• Temporal normalization: Alignment across databases with different reporting cadences, lag times, and date format conventions to enable valid cross-source temporal analyses
• CDISC compliance: Clinical trial data integrated via CDISC SDTM and ADaM standards, ensuring interoperability with sponsor datasets and regulatory submission formats

Every data source carries inherent biases and quality limitations that must be characterized for responsible interpretation. The platform applies automated quality assessment at every stage:

Automated Quality Scoring:

• Completeness scoring: percentage of required fields populated, weighted by analytical importance
• Consistency checks: cross-field validation, temporal plausibility, and dosage-indication coherence
• Data quality scorecards generated for each analysis, documenting the evidence quality underpinning every conclusion

Deduplication:

• Probabilistic record linkage algorithms identify and reconcile duplicate reports across FAERS, EudraVigilance, and VigiBase
• Follow-up report consolidation preserves the most complete version of each case while maintaining full case history

Bias Characterization:

• Reporting bias: Weber effect modeling, notoriety bias detection, and stimulated reporting adjustment for spontaneous report data
• Selection bias: Demographic profiling against expected population distributions with stratified subgroup analysis
• Confounding: Stratification, multivariate adjustment, and propensity score methods where individual-level data is available
• Publication bias: Funnel plot analysis and Egger's regression for systematic review components
• Missing data: Pattern analysis (MCAR/MAR/MNAR classification) with multiple imputation and sensitivity analysis where appropriate

The platform encodes regulatory guidance from multiple authorities directly into its analytical workflows, enabling teams to generate jurisdiction-specific outputs from a single integrated evidence base:

• FDA: Structured Benefit-Risk Assessment Framework (PDUFA V/VI), CFR Title 21, ICH E2C(R2) implementation for PBRER, IND Safety Reporting (21 CFR 312.32)
• EMA: GVP Modules V (Risk Management), VII (PSUR/PBRER), IX (Signal Management), PRAC assessment workflows, PROTECT quantitative BRA recommendations
• PMDA: Japanese pharmacovigilance requirements, J-PSUR format compliance, RMP generation in Japanese, PMDA-specific safety reporting thresholds
• Health Canada: Summary Basis of Decision requirements, Canadian Vigilance Program compatibility, Risk Management Plan standards
• ICH harmonization: M4E(R2) for CTD structure, E2E for pharmacovigilance planning, E2C(R2) for PBRER, CIOMS IV/VIII/X/XI methodological standards

• "Quantitative Benefit-Risk Analysis at Scale: Lessons from 50+ Regulatory Submissions." International Society for Pharmacoepidemiology (ISPE) Annual Meeting, 2025. Oral presentation.
• "Domain-Specific AI for Pharmacovigilance Signal Detection: Moving Beyond Disproportionality." Drug Information Association (DIA) Annual Meeting, 2025. Symposium presentation.
• "Automated PBRER Generation with Integrated Benefit-Risk Evaluation: A Platform Validation Study." European Medicines Agency Pharmacovigilance Stakeholder Forum, 2024. Poster presentation.
• "NLP-Based Adverse Event Extraction from Multilingual Regulatory Documents: Performance Benchmarking." Society for Clinical Data Management (SCDM) Annual Conference, 2024. Oral presentation.
• "Multi-Criteria Decision Analysis in Regulatory Benefit-Risk Assessment: Practical Implementation and Stakeholder Engagement." CIOMS Seminar on Benefit-Risk Assessment, 2023. Invited lecture.

View all publications and presentations →